Medical oncology in the management of head and neck cancers

Otolaryngologic Clinics of North America

Volumn 31, Issue 5, 1998, Pages 881-905

  Lilly, S G ^a   Lilly, G E ^a   Marek, C L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIMETABOLITE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN SULFATE; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; LOMUSTINE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITHRAMYCIN; MITOXANTRONE; NITROSOUREA DERIVATIVE; PROCARBAZINE; THIOTEPA; UNINDEXED DRUG; URAMUSTINE; VINBLASTINE;

ALOPECIA; ARTICLE; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER STAGING; HEAD AND NECK CARCINOMA; HUMAN; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; LYMPH NODE METASTASIS; MUCOSA INFLAMMATION; MUSCLE DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; SKIN TOXICITY; SMOKING; TUMOR SUPPRESSOR GENE; VOMITING;

EID: 0031770092     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0030-6665(05)70094-3     Document Type: Article

References (131)

1. Adelstein DJ, Saxton JP, Laverter P, et al. Concurrent radiation and chemotherapy versus radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: A phase III randomized trial (abstract 15:2015) Proc ASCO 1996; sup page 26, Proceedings of the American Society of Clinical Oncology. Thirty-second Annual Meeting. May 18–21, 1996. Philadelphia
2. J. Aisner D. Hiponia B. Conley Combined modalities in the treatment of head and neck cancers Semin Oncol 22 suppl 6 1995 28 34
3. Al-Sarraf M, LeBlanc M, Giri PGS, et al. Superiority of chemo-radiotherapy vs radiotherapy in patients with locally advanced nasopharyngeal cancer: Preliminary results of intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 388) randomized study. Proc ASCO 15:313, 1996 Proceedings of the American Society of Clinical Oncology. Thirty-second Annual Meeting. May 18–21, 1996. Philadelphia
4. Ambinder RF. Phase I pilot study of azacytidine by 7-day continuous infusion in relapsed and/or refractory EBV-associated malignancies. J HOC—T93-0175, NCI-T-93-0175D Ongoing clinical trial-National Cancer Institute Protocol
5. J.A. Anderson J.C. Irish C.M. McLachlin H-ras oncogene mutation and human papillomavirus infection in oral carcinomas Arch Otolaryngol Head Neck Surg 120 1994 755 760
6. K. Anwar K. Nakakuki H. Naiki ras gene mutations and HPV infection are common in human laryngeal carcinoma Int J Cancer 53 1993 22 28
7. J.R. Bischoff D.H. Kirn A. Williams An adenovirus mutant that replicates selectively in p53 -deficient human tumor cells Nature 274 1996 373 376
8. M. Bolla R. Lefur J. Ton Van Prevention of second primary tumors with etretinate in squamous cell carcinoma of the oral cavity and oropharynx: Results of a multicentric double-blind randomized study Eur J Cancer 6 1994 767 772
9. J. Bourhis J. Bosq G.D. Wilson Correlation between p53 gene expression and tumor-cell proliferation in oropharyngeal cancer Int J Cancer 57 1994 458 462
10. Bourhis J, Lubin R, Roche B, et al. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. (abstract 15:899) Proc ASCO 1996 pg 317.
11. J.O. Boyle J. Hakim W. Koch The incidence of p53 mutations increases with progression of head and neck cancer Cancer Res 53 1993 4477 4480
12. C. Bradford S. Zhu G.T. Wolf Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer Otolaryngol Head Neck Surg 113 1995 408 412
13. J.A. Brennan J.O. Boyle W.M. Koch Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck N Engl J Med 332 1995 712 717
14. J.A. Brennan L. Mao R.H. Hruban Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck N Engl J Med 332 1995 429 435
15. Brizel DM, Albers ME, Fisher SR, et al. A prospective randomized trial of hyperfractionated irradiation with and without concurrent chemotherapy for locally advanced carcinoma of the head and neck. Submitted for publication, 1997.
16. R.L. Capizzi Amifostine: The preclinical basis for broad-spectrum selective cytoprotection of normal tissues for cytotoxic therapies Semin Oncol 23 suppl 8 1986 2 17
17. Chevallier BG. Phase II study of vinorelbine for metastatic or locally recurrent squamous cell carcinoma of the head and neck outside previously irradiated fields. EORTC (Protocol 04942) Ongoing clinical trial. European Organization for Research and Treatment of Cancer
18. F. Chiesa N. Tradat M. Marraza Prevention of local relapses and new localization with synthetic retinoid fenretinide (4-HPR): Preliminary results Eur J Cancer 28 1992 97 102
19. K.Y. Chung T. Mukhopadhyay J. Kim Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract Cancer Res 53 1993 1676 1683
20. G.L. Clayman A.K. El-Naggar J.A. Roth In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma Cancer Res 55 1995 1 6
21. G.L. Clayman M.G. Stewart R.S. Weber Human papillomavirus in laryngeal and hypopharyngeal carcinomas Arch Otolaryngol Head Neck Surg 120 1994 743 748
22. J.S. Cooper T.F. Pajak P. Rubin Second malignancies in patients who have head and neck cancer: Incidence, effect or survival and implications based on the RTOG experience Int J Radiat Oncol Biol Phys 17 1989 449 456
23. Couteau C, Leyvraz S, Oulid-Aissa D, et al. A phase II study of docetaxel in squamous cell carcinoma of the head and neck. (abstract 15:889) Proc ASCO 1996, pg 315 Proceedings of the American Society of Clinical Oncology. Thirty-second Annual Meeting. May 18–21, 1996, Philadelphia
24. T. Crook J.A. Tidy K.H. Vousden Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and transactivation Cell 67 1991 547 556
25. R.C. DeConti D. Schoenfeld A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer Cancer 48 1981 1061 1072
26. Department of Veterans Affairs Laryngeal Cancer Study Group Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer N Engl J Med 324 1991 1685 1690
27. E.M. De Villiers H. Weidauer H. Otto Papillomavirus DNA in human tongue cancers Int J Cancer 36 1985 575 578
28. J.T. DiPiro R.C. Talbert G.C. Yee Pharmacotherapy: A Patho-physiologic Approach ed 3 1997 Appleton & Lange Stamford CT
29. J.B. Epstein F.L.W. Wong A. Millner Topical bleomycin treatment of oral leukoplakia: A randomized double-blind clinical trial Head Neck 16 1994 539 544
30. A.R. Feinstein Clinical biostatistics: XLI. Hard science, soft data, and the challenges of choosing clinical variables in research Clin Pharmacol Ther 22 1977 485
31. J.K. Field Genomic instability in squamous cell carcinoma of the head and neck Anticancer Res 16 1996 2421 2432
32. J.K. Field A. Malliri S.A. Butt p53 overexpression in end stage squamous cell carcinoma of the head and neck correlates with a very poor clinical outcome Int J Oncol 3 1993 431 435
33. A.A. Forastiere Overview of platinum chemotherapy in head and neck cancer Semin Oncol 21 1994 20 27
34. A.A. Forastiere Randomized trials of induction chemotherapy: A critical review Hematol Oncol Clin North Am 5 1991 725 736
35. A.A. Forastiere B. Metch D.E. Schuller Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: A Southwest Oncology Group study J Clin Oncol 10 1992 1245 1251
36. P. Fouret F. Martin A. Flahault Human papillomavirus infection in the malignant and premalignant head and neck epithelium Diagn Mol Pathol 4 1995 122 127
37. J.F. Fries P.W. Spitz The hierarchy of patient outcome B. Spilker Quality of Life Assessments in Clinical Trials 1990 Raven Press New York 25
38. T. Fujiwara E.A. Grimm T. Mukhopadhyay Induction of chemosensitivity in human lung cancer cell in vivo by adenovirus-mediated transfer of the wild-type p53 gene Cancer Res 54 1994 2287
39. J. Gasmi M. Bachouch E. Costkauic Nasopharyngeal carcinoma, a medical oncology viewpoint: The Gustave Roussy experience Ann Oncol 1 1990 245 253
40. S.C. Girod G. Krueger H.D. Pape p53 and Ki67 expression in preneoplastic and neoplastic lesions of the oral mucosa Int J Oral Maxillofac Surg 22 1993 285 288
41. D.K. Goette Topical chemotherapy with 5-fluorouracil J Am Acad Dermatol 4 1981 633
42. M.S. Greenblatt W.P. Bennett M. Hollstein Mutations in the p53 tumor-suppressor gene: Clues to cancer etiology and molecular pathogenesis Cancer Res 54 1994 4855 4878
43. J. Han Y. Lu Z. Sun Evaluation of N-4-(hydroxycarbophenyl) retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent In Vivo 4 1990 153 160
44. C.H. Hennekens J.E. Buring J.E. Manson Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease N Engl J Med 334 1996 1145 1149
45. P.J. Hesketh W.H. Harvey T.M. Harker A randomized double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in prevention of high-dose cisplatin-induced emesis J Clin Oncol 12 1994 596 600
46. Hoffmann W, Schmidberger H, Hess CF, et-al. Phase I study with weekly paclitaxel and simultaneous radiation in locally advanced inoperable squamous cell carcinoma of the head and neck. (abstract 15:914) Proc ASCO 1996, pg 321 Proceedings of the American Society of Clinical Oncology. Thirty-second Annual Meeting. May 18–21, 1996, Philadelphia
47. W.K. Hong J. Endicott L.M. Itri 13- cis -retinoic acid in the treatment of oral leukoplakia N Engl J Med 315 1986 1501 1505
48. W.K. Hong S.M. Lippman L.M. Itri Prevention of secondary primary tumors with isotretinoin in squamous cell carcinoma of the head and neck N Engl J Med 323 1990 795 801
49. Horiuchi M, Inuyama Y, Miyake H. Efficacy of surgical adjuvant with tegafur and uracil (UFT) in resectable head and neck cancer: A prospective randomized study. (abstract 13:284) Proc ASCO 1994 Proceedings of the American Society of Clinical Oncology. Thirtieth Annual Meeting. May 14–17, 1994, Dallas
50. P.M. Howley Viral carcinogenesis J. Mendelsohn P.M. Howley M.A. Israel The Molecular Basis of Cancer 1995 WB Saunders Philadelphia 38 58
51. S.C. Huang Nasopharyngeal cancer: A review of 1605 patients treated radically with cobalt 60 Int J Radiat Oncol Biol Phys 6 1980 401 407
52. T. Jacks R.A. Weinberg Cell-cycle control and its watchman Nature 381 1996 643 644
53. E. Jacobs G. Lyman E. Velez-Garcia A phase III randomized study comparing cisplatin and fluorouracil as single agent and in combination for advanced squamous cell carcinoma of the head and neck J Clin Oncol 10 1992 257 263
54. J. Jakush New fluoride schedule adopted ADA News May 16 12 1994 14
55. Kambhu S, Clamon G, Doornbos F, et al. Phase II trial of taxol and cisplatin in advanced squamous cell carcinoma of the head and neck. (abstract 15:917) Proc ASCO 1996, pg 322 Proceedings of the American Society of Clinical Oncology. Thirty-second Annual Meeting. May 18–21, 1996, Philadelphia
56. H.K. Kashima M. Kutcher T. Kessis Human papillomavirus in squamous cell carcinoma, leukoplakia, lichen planus, and clinically normal epithelium of the oral cavity Ann Otol Rhinol Laryngol 99 1990 55 61
57. M.B. Kastan O. Onyekere D. Sidransky Participation of p53 protein in the cellular response to DNA damage Cancer Res 51 1991 6304 6311
58. W. Kelker D.L. Van Dyke M.J. Worsham Loss of 18 q and homozygosity for the DCC locus: Possible markers for clinically aggressive squamous cell carcinoma Anticancer Res 16 1996 2365 2372
59. J.A. Kish A. Weaver J. Jacobs Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck Cancer 53 1984 1818 1824
60. H.F. Koch Biochemical treatment of precancerous oral lesions: The effectiveness of various analogues of retinoic acid J Maxillofac Surg 6 1978 59 63
61. W.M. Koch J.O. Boyle L. Mao p53 gene mutations as markers of tumor spread in synchronous oral cancers Arch Otolaryngol Head Neck Surg 120 1994 943 947
62. L.H. Kushi A.R. Folsom R.J. Prineas Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women N Engl J Med 334 1996 1156 1162
63. Ladd TE. Phase II study of aminocamptothecin for advanced squamous cell carcinoma of the head and neck. Protocol UCCRC-8014, NCI-195-00834 Ongoing clinical trial. National Cancer Institute Protocol
64. D.P. Lane A death in the life of p53. Nature 362 1993 786 787
65. G.E. Laramore C.B. Scott M. al-Sarraf Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report on Intergroup Study 0034 Int J Radiat Oncol Biol Phys 23 1992 705 713
66. Latreille J, Stewart D, Laberge F, et al. Dexamethasone improves the efficacy of granisetron in the first 24 hours following high dose cisplatin chemotherapy (abstract 12:133). Proc ASCO 1993 Proceedings of the American Society of Clinical Oncology. Twenty-ninth Annual Meeting. May 16–18, 1993, Orlando
67. J.P. Lavieille R. Lubin T. Soussi Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck Anticancer Res 16 1996 2385 2388
68. Lefebvre JL, Sahmond T, for the EORTC Head and Neck Cancer Cooperative Group. Larynx preservation in hypopharynx squamous cell carcinoma: Preliminary results of a randomized study. (EORTC 24891). (abstract 13:283) Proc ASCO 1995 Proceedings of the American Society of Clinical Oncology. Thirty-first Annual Meeting. May 20–23, 1995, Los Angeles
69. J.L. Lefebvre D. Chevalier B. Luboinski Larynx preservation in pyriform sinus cancer: Preliminary results of a European organization for research and treatment of cancer phase III trial EORTC Head and Neck Cancer Cooperative Groups J Natl Cancer Inst 88 13 1996 890 899
70. D. Liebovitz Nasopharyngeal carcinoma: The Epstein-Barr virus association Semin Oncol 21 1994 376 381
71. S.M. Lippman J.G. Batsakis B.B. Toth Comparison of low-dose isotretinoin with beta-carotene to prevent oral carcinogenesis N Engl J Med 328 1993 15 20
72. S.M. Lippman S.E. Benner W.K. Hong Cancer chemoprevention J Clin Oncol 12 1994 851 873
73. S.M. Lippman S.E. Benner W.K. Hong The chemoprevention of cancer P. Greenwald R.S. Kramer D.L. Weed Cancer Prevention and Control 1995 Marcel Dekker New York 329 352
74. S.M. Lippman J.F. Kessler F.L. Meyskens Retinoids as preventive and therapeutic anticancer agents Cancer Treat Res 71 1987 391 405 493–515
75. S.M. Lippman D.M. Shin J.J. Lee p53 and retinoid chemoprevention of oral carcinogenesis Cancer Res 55 1995 16 19
76. S.M. Lippman M.R. Spritz M.H. Huber Strategies for chemoprevention study of premalignancy and second primary tumors in the head and neck Curr Opin Oncol 7 1995 234 241
77. S.M. Lippman W.K. Hong Retinoid chemoprevention of upper aerodigestive tract carcinogenesis V.T. DeVita S. Hellman S.A. Rosenberg Important Advances in Oncology 1992 JB Lippincott Philadelphia 93 109
78. T.-J. Liu W.-W. Zhang D.L. Taylor Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus Cancer Res 54 1994 3662 3667
79. L.R. Livingstone A. White J. Sprouse Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70 1992 923 935
80. R. Lotan M.I. Dawson C.-C. Zou Enhanced efficacy of combinations of retinoic acid- and retinoid X receptor-selective retinoids and α-interferon in inhibition of cervical carcinoma cell proliferation Cancer Res 55 1995 232 236
81. S.W. Lowe S. Bodis A. McClatchey p53 status and the efficacy of cancer therapy in vivo Science 266 1994 807 810
82. S.W. Lowe H.E. Ruley T. Jacks p53 -dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 74 1993 959 967
83. Mascarin M, Franchin G, Minatel M, et al. The effect of Filgastrim (G-CSF) on mucositis in head and neck patients treated with hyperfractionated radiotherapy. (abstract 15:739) Proc ASCO 1996, pg 276 Proceedings of the American Society of Clinical Oncology. Thirty-second Annual Meeting. May 18–21, 1996, Philadelphia
84. M. Masuda N. Hirakawa T. Nakashima Cyclin D1 overexpression in primary hypopharyngeal carcinomas Cancer 78 1996 390 395
85. H.M. Maurer M. Beltangady E.A. Gehan The Intergroup Rhabdomyosarcoma Study group I: A final report Cancer 61 1988 209 220
86. S. McCormick Intralesional vinblastine injections for the treatment of oral Kaposi's sarcoma J Oral Maxillofac Surg 54 1996 583 587
87. M. Merlano M. Benasso R. Corro Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in the treatment of unresectable squamous cell carcinoma of the head and neck J Natl Cancer Inst 88 1996 583 589
88. M. Merlano V. Vitale B. Rosso Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy N Engl J Med 327 1992 1115 1121
89. J.D.H. Morris A.L.W.F. Eddleston T. Crook Viral infection and cancer Lancet 346 1995 754 758
90. A.J. Munro An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer Br J Cancer 71 1995 83 91
91. S. Nakamura A. Hiroki M. Shinohara Oral involvement in chronic graft-versus-host disease after allogeneic bone marrow transplantation Oral Surg Oral Med Oral Pathol Oral Radiol Endod 82 1996 556 563
92. National Cancer Institute Consensus Development Conference on Oral Complications of Cancer Therapies: Diagnosis, Prevention, and Treatment National Cancer Institute Monograph vol 9 1990 National Cancer Institute Bethesda, MD 1 10
93. M. Nees N. Homawn H. Discher Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: A possible molecular basis for the development of multiple tumors Cancer Res 53 1993 4189 4196
94. G.S. Omenn G.E. Goodman M.D. Thornquist Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease N Engl J Med 334 1996 1150 1155
95. C. Ostwald P. Muller M. Barten Human papillomavirus DNA in oral squamous cell carcinomas and normal mucosa J Oral Pathol Med 23 1994 220 225
96. A. Paccagnella A. Orlando C. Marchiori Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori Della Testa e del Collo J Natl Cancer Inst 86 1994 265 272
97. S. Parker T. Tong S. Bolden Cancer statistics, 1997 CA Cancer J Clin 47 1997 5 27
98. C.A. Perez Carcinoma of the nasopharynx L.W. Brady C. Peser Principles and Practice of Radiation Oncology ed 2 1992 JB Lippincott Philadelphia 617 644
99. D.E. Peterson Oral toxicity of chemotherapeutic agents Semin Oncol 19 1992 478 491
100. D.E. Peterson Toxicity of chemotherapy induced oral lesions M.C. Perry S.W. Yarbro Toxicity of Chemotherapy 1984 Grune and Stratton New York 155 180
101. D.G. Pfister E. Strong L. Harrison Larynx preservation with combined chemotherapy and radiation therapy in advanced but resectable head and neck cancer J Clin Oncol 9 1991 850 859
102. Physicians' Desk Reference ed 51 1997 Medical Economics, Inc. Montvale, NJ
103. Posner M, Dreyfuss A, Clark J, et al. Docetaxel for advanced incurable squamous cell carcinoma of the head and neck. (abstract 15:872) Proc ASCO 1996, pg 311.
104. A. Razek C.A. Perez M. Tefft Intergroup Ewing's sarcoma study: Local control related to radiation dose, volume, and site of primary lesion in Ewing's sarcoma Cancer 46 1980 516 521
105. S.W. Redding National Cancer Institute: Role of Herpes Simplex Virus Reactivation in Chemotherapy-Induced Oral Mucositis National Cancer Institute Monograph vol 9 1990 National Cancer Institute Bethesda, MD 103 105
106. F. Roila M. Tonato F. Cognetti Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone J Clin Oncol 9 1991 675 678
107. J.A. Roth D. Nguyen D.D. Laurence Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer Nature Med 2 1996 985 991
108. E. Sakai N. Tsuchida Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes Oncogene F 1992 927 933
109. M. Scheffner B.A. Werness J.M. Hurbregtse The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 1990 1129
110. Schoffski P, Wanders J, Catimel G, et al. Docetaxel and cisplatin: A highly active regimen for squamous cell carcinoma of the head and neck. (abstract 15:871) Proc ASCO 1996, pg 310 Proceedings of the American Society of Clinical Oncology. Thirty-second Annual Meeting. May 18–21, 1996, Philadelphia
111. D.M. Shin J.S. Lee S.M. Lippman p53 expression: Predicting recurrence and second primary tumors in head and neck squamous cell carcinoma J Natl Cancer Inst 88 1996 519 529
112. D.M. Shin J. Kim J.Y. Ro Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis Cancer Res 54 1994 321 326
113. M. Shindoh Y. Sawada T. Kohgo Detection of human papillomavirus DNA sequences in tongue squamous-cell carcinoma utilizing the polymerase chain reaction method Int J Cancer 50 1992 167 171
114. D.P. Slaughter H.W. Southwick W. Smejkal Field cancerization: In oral stratified squamous epithelium Cancer 6 1953 963 968
115. M.R. Spaulding S.G. Fischer G.T. Wolf Tumor response toxicity and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma J Clin Oncol 12 1994 1592 1599
116. P.M. Stell Adjuvant chemotherapy in head and neck cancer Semin Radiat Oncol 2 1993 195 205
117. H.F. Stich A.P. Hornby B. Mathew Response of oral leukoplakias to the administration of vitamin A Cancer Lett 40 1988 93 101
118. P.J. Sweeney D.J. Haraf E.E. Voke Radiation therapy in head and neck cancer: Indications and limitations Semin Oncol 21 1994 296 303
119. Y.-S. Tyan S.-T. Liu W.-R. Ong Detection of Epstein-Barr virus and human papillomavirus in head and neck tumors J Clin Microbiol 31 1993 53 56
120. S.G. Urba A.A. Forastiere G.T. Wolf Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma J Clin Oncol 12 1994 946 953
121. USPDI ed 17 Drug Information for the Health Care Professional vol 2 1997 The United States Pharmacopeial Convention Rockville, MD
122. W.R. Vogler J. Jacobs S. Moffitt Methotrexate therapy with or without citrovorum factor in carcinoma of the head and neck, breast, and colon Cancer Clinical Trials 2 1979 227 236
123. E.E. Vokes R.R. Weichselbaum S.M. Lippman Head and neck cancer N Engl J Med 328 1993 184 194
124. K.H. Vousden Human papillomavirus and cervical carcinoma Cancer Cell 1 1989 43 50
125. T.H. Wasserman Radiotherapeutic studies with Amifostine (ethyol) Semin Oncol 21 suppl 11 1994 21 25
126. Wasserman T, Brizel D. Phase III trial of radiation therapy ± Amifostine in patients with head and neck cancer. (ongoing trial WR-38)
127. T.L. Whiteside K. Chikamatsu S. Nagashima Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer Anticancer Res 16 1996 2357 2364
128. Winn RJ. Pilot study of the feasibility of performing a chemoprevention trial through community clinical oncology programs (CCOPs) using vitamin E to treat oral leukoplakia. Protocol MDA-DM-88107, NCI-C88-0009, NCI-P91-0005 Ongoing clinical trial. National Cancer Institute Protocols
129. G. Wolf S.M. Lippman G. Laramori Head and neck cancer J.F. Holland E. Frei R.C. Bast Jr Cancer Medicine ed 3 1993 Lea & Febiger Philadelphia 1211 1278
130. R.C. Wood Involvement of methionine in the synthesis of certain membrane-associated nucleotide sugars by human amnion (WISH) cells Cancer Lett 100 1996 37 40
131. Y. Yin M.A. Tainsky F.Z. Bischoff Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles Cell 70 1992 937 948